Business Context and Reporting Period
This Form 8-K Current Report was filed by ChromaDex Corp. on January 24, 2012, covering events occurring on January 22 and January 23, 2012. The filing primarily addresses significant changes in executive leadership.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance data.
Material Changes
- Executive Appointment: Jeffrey Himmel was appointed as Chief Executive Officer (CEO), effective January 23, 2012.
- Role Transition: Frank Jaksch, Jr., previously the CEO and a Board member, was appointed as Chief Scientific Officer. He remains a member of the Board of Directors.
- Background: Mr. Himmel brings experience as the former Chairman of The Himmel Group, with a history of building consumer packaged goods brands such as OVALTINE and GOLD BOND MEDICATED POWDER.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements cautioning that future plans and performance are subject to uncertainties, specifically citing the risk of securing capital for general working purposes. The Company disclaims any obligation to update these statements. No specific financial guidance or outlook was provided in this document.
Investor Verification Checklist
- Verify the effective date of Jeffrey Himmel's appointment as CEO (January 23, 2012).
- Confirm Frank Jaksch, Jr.'s new title as Chief Scientific Officer and continued Board membership.
- Review the attached Press Release (Exhibit 99.1) for additional details on the leadership transition.
- Check subsequent filings for financial data, as this 8-K contains no revenue or earnings figures.